| Autor: |
Brandl M; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany., Schmidt AJ; Sigma Research, Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine (LSHTM), London, United Kingdom., Marcus U; Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany., Duffell E; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Severi E; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Mozalevskis A; World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark., Kivite-Urtane A; Institute of Public Health, Riga Stradins University, Riga, Latvia., An der Heiden M; Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany., Dudareva S; Department of Infectious Disease Epidemiology, Robert Koch Institute (RKI), Berlin, Germany. |
| Abstrakt: |
BackgroundHepatitis A and B vaccinations are recommended for men who have sex with men (MSM), given their increased risk of infection. However, data on vaccination programmes are scarce.AimTo use information on vaccination recommendations and vaccine uptake among MSM in the WHO European Region to guide prevention.MethodsFrom a large pan-European MSM Internet Survey (EMIS-2017), we analysed data on self-reported hepatitis A and B vaccination status by age, education, financial coping, settlement size, outness (disclosure of sexual behaviour), migration history and diagnosis with hepatitis C or HIV, using multivariable logistic regression. Additionally, we collected information on national hepatitis A and B vaccination recommendations.ResultsWe present data of 113,884 MSM, median age 36 years (IQR: 27-47). Vaccination for hepatitis A and B was recommended and free for MSM in 7 and 18 of 43 countries, respectively. Of all respondents, 48% (n = 50,966) reported ever being vaccinated against hepatitis A, and 53% (n = 56,889) against hepatitis B. Odds for being vaccinated against hepatitis A increased with outness ('out to (almost) all' aOR: 1.78, 95% CI: 1.72-1.85 vs 'out to none') and were higher in countries where vaccination was recommended and free for MSM (aOR: 2.22, 95% CI: 1.29-3.82 vs 'no recommendation'). Results for hepatitis B were similar (outness: aOR: 1.81, 95% CI: 1.75-1.88 and MSM-specific vaccination recommendation: aOR: 2.44, 95% CI: 1.54-3.85).ConclusionLarge proportions of MSM in Europe remain vulnerable to hepatitis A and B, despite available vaccination. Implementation of MSM-specific vaccination recommendations and greater efforts to improve the societal climate for MSM are needed to address gaps in vaccine coverage. |
